{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:29:01Z","timestamp":1768001341698,"version":"3.49.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019888","name":"University of Kentucky College of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xphs.2023.08.026","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T01:53:09Z","timestamp":1693792389000},"page":"711-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation"],"prefix":"10.1016","volume":"113","author":[{"given":"Preye","family":"Agbana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rychahou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Bo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1360-3524","authenticated-orcid":false,"given":"Younsoo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2023.08.026_bib0001","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1039\/c3np20126k","article-title":"From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes","volume":"30","author":"Kim","year":"2013","journal-title":"Nat Prod Rep"},{"issue":"2","key":"10.1016\/j.xphs.2023.08.026_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2023.08.026_bib0003","first-page":"307","article-title":"Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents","volume":"4","author":"Kurtin","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.xphs.2023.08.026_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl Res"},{"issue":"9","key":"10.1016\/j.xphs.2023.08.026_bib0005","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.xphs.2023.08.026_bib0006","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.xphs.2023.08.026_bib0007","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.xphs.2023.08.026_bib0008","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsnonproteasomal targets of proteasome inhibitors","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.xphs.2023.08.026_bib0009","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.3390\/ijms222111595","article-title":"Proteasome inhibitors and their pharmacokinetics, pharmacodynamics, and metabolism","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.08.026_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","article-title":"Positioning of proteasome inhibitors in therapy of solid malignancies","volume":"81","author":"Roeten","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.xphs.2023.08.026_bib0011","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","article-title":"Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy","volume":"18","author":"Zang","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0012","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"17","key":"10.1016\/j.xphs.2023.08.026_bib0013","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"US Food and Drug administration approval: carfilzomib for the treatment of multiple MyelomaFDA approval summary of carfilzomib","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.08.026_bib0014","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2023.08.026_bib0015","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/mp300044b","article-title":"Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib","volume":"9","author":"Ao","year":"2012","journal-title":"Mol Pharmac"},{"key":"10.1016\/j.xphs.2023.08.026_bib0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2014.10.005","article-title":"Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo","volume":"196","author":"Ashley","year":"2014","journal-title":"J Controlled Release"},{"issue":"11","key":"10.1016\/j.xphs.2023.08.026_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02922-9","article-title":"Ternary polypeptide nanoparticles with improved encapsulation, sustained release, and enhanced in vitro efficacy of carfilzomib","volume":"37","author":"Agbana","year":"2020","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2023.08.026_bib0018","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.xphs.2021.09.022","article-title":"Effects of organic acids on drug release from ternary polypeptide nanoparticles entrapping carfilzomib","volume":"111","author":"Jackson","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.08.026_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02922-9","article-title":"Ternary polypeptide nanoparticles with improved encapsulation, sustained release, and enhanced in vitro efficacy of carfilzomib","volume":"37","author":"Agbana","year":"2020","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2023.08.026_bib0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/jpet.115.226993","article-title":"Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines","volume":"355","author":"Ao","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2023.08.026_bib0021","doi-asserted-by":"crossref","first-page":"620.1","DOI":"10.1096\/fasebj.29.1_supplement.620.1","article-title":"Nanoformulations of carfilzomib for improved metabolic stability and anti-cancer efficacy","volume":"29","author":"Ao","year":"2015","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.xphs.2023.08.026_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173247","article-title":"Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: anticancer efficacy and pharmacokinetic studies in mice","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2023.08.026_bib0023","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11095-016-2070-6","article-title":"Comparison of dialysis-and Solvatofluorochromism-based methods to determine drug release rates from polymer nanoassemblies","volume":"34","author":"Reichel","year":"2017","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0024","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4155\/tde-2016-0041","article-title":"Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity","volume":"7","author":"Reichel","year":"2016","journal-title":"Therap Deliv"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0025","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4155\/tde.15.59","article-title":"Polymer nanoassemblies with solvato-and halo-fluorochromism for drug release monitoring and metastasis imaging","volume":"6","author":"Reichel","year":"2015","journal-title":"Therap Deliv"},{"issue":"14","key":"10.1016\/j.xphs.2023.08.026_bib0026","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/adma.201405084","article-title":"Interfacing materials science and biology for drug carrier design","volume":"27","author":"Such","year":"2015","journal-title":"Adv Mater"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0027","doi-asserted-by":"crossref","first-page":"1800917","DOI":"10.1002\/marc.201800917","article-title":"pH-responsive polymer nanoparticles for drug delivery","volume":"40","author":"Deirram","year":"2019","journal-title":"Macromol Rapid Commun"},{"issue":"8","key":"10.1016\/j.xphs.2023.08.026_bib0028","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/nano10081613","article-title":"pH-responsive nanoparticles for cancer immunotherapy: a brief review","volume":"10","author":"Yan","year":"2020","journal-title":"Nanomaterials"},{"issue":"12","key":"10.1016\/j.xphs.2023.08.026_bib0029","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nnano.2012.207","article-title":"Biomolecular coronas provide the biological identity of nanosized materials","volume":"7","author":"Monopoli","year":"2012","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/j.xphs.2023.08.026_bib0030","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/ja2084338","article-title":"Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake","volume":"134","author":"Walkey","year":"2012","journal-title":"J Am Chem Soc"},{"issue":"2","key":"10.1016\/j.xphs.2023.08.026_bib0031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13404-011-0018-5","article-title":"Controlled spontaneous generation of gold nanoparticles assisted by dual reducing and capping agents","volume":"44","author":"Dumur","year":"2011","journal-title":"Gold Bull"},{"issue":"3","key":"10.1016\/j.xphs.2023.08.026_bib0032","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1148\/radiology.187.3.8497616","article-title":"A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies","volume":"187","author":"Bogdanov Jr","year":"1993","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.xphs.2023.08.026_bib0033","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1021\/bc0000177","article-title":"pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly (L-histidine)-graft-poly (L-lysine) comb shaped polymer","volume":"11","author":"Benns","year":"2000","journal-title":"Bioconjugate Chem"},{"issue":"3","key":"10.1016\/j.xphs.2023.08.026_bib0034","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0168-3659(03)00205-0","article-title":"Poly (l-histidine)\u2013PEG block copolymer micelles and pH-induced destabilization","volume":"90","author":"Lee","year":"2003","journal-title":"J Controlled Rel"},{"issue":"11","key":"10.1016\/j.xphs.2023.08.026_bib0035","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/mabi.200500121","article-title":"pH-induced micelle formation of poly (histidine-co-phenylalanine)-block-poly (ethylene glycol) in aqueous media","volume":"5","author":"Kim","year":"2005","journal-title":"Macromol Biosci"},{"issue":"2","key":"10.1016\/j.xphs.2023.08.026_bib0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2004.12.018","article-title":"Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor","volume":"103","author":"Lee","year":"2005","journal-title":"J Controlled Release"},{"issue":"126","key":"10.1016\/j.xphs.2023.08.026_bib0037","doi-asserted-by":"crossref","first-page":"104239","DOI":"10.1039\/C5RA20192F","article-title":"The assembly of polyethyleneimine-entrapped gold nanoparticles onto filter paper for catalytic applications","volume":"5","author":"Liu","year":"2015","journal-title":"RSC Adv"},{"key":"10.1016\/j.xphs.2023.08.026_bib0038","doi-asserted-by":"crossref","unstructured":"Aymonier C., Schlotterbeck U., Antonietti L., et al. Hybrids of silver nanoparticles with amphiphilic hyperbranched macromolecules exhibiting antimicrobial properties. Chem Commun. 2002;(24):3018\u20133019.","DOI":"10.1039\/b208575e"},{"issue":"5","key":"10.1016\/j.xphs.2023.08.026_bib0039","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/am302883m","article-title":"Facile hydrothermal synthesis and surface functionalization of polyethyleneimine-coated iron oxide nanoparticles for biomedical applications","volume":"5","author":"Cai","year":"2013","journal-title":"ACS Appl Mater Interfaces"},{"issue":"104","key":"10.1016\/j.xphs.2023.08.026_bib0040","doi-asserted-by":"crossref","first-page":"101790","DOI":"10.1039\/C6RA19351J","article-title":"Polyethyleneimine-stabilized hydroxyapatite nanoparticles modified with hyaluronic acid for targeted drug delivery","volume":"6","author":"Kong","year":"2016","journal-title":"RSC Adv"},{"issue":"5","key":"10.1016\/j.xphs.2023.08.026_bib0041","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s11095-014-1573-2","article-title":"Release, partitioning, and conjugation stability of doxorubicin in polymer micelles determined by mechanistic modeling","volume":"32","author":"Ponta","year":"2015","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2023.08.026_bib0042","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00018-020-03620-w","article-title":"Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas","volume":"78","author":"Jeitany","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0043","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.3390\/ijms21103622","article-title":"Proteasome inhibitors as a possible therapy for SARS-CoV-2","volume":"21","author":"Longhitano","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.xphs.2023.08.026_bib0044","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/1535-7163.MCT-17-0541","article-title":"Sorafenib and carfilzomib synergistically inhibit the proliferation, survival, and metastasis of hepatocellular carcinomacombination of sorafenib and carfilzomib against HCC","volume":"17","author":"Jiang","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"10.1016\/j.xphs.2023.08.026_bib0045","doi-asserted-by":"crossref","first-page":"29102","DOI":"10.18632\/oncotarget.8667","article-title":"Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia\/lymphoma","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.xphs.2023.08.026_bib0046","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2\u201310-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"10.1016\/j.xphs.2023.08.026_bib0047","doi-asserted-by":"crossref","first-page":"13698","DOI":"10.1039\/C5RA26563K","article-title":"The evaluation of cellular uptake efficiency and tumor-targeting ability of MPEG\u2013PDLLA micelles: effect of particle size","volume":"6","author":"Hao","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.xphs.2023.08.026_bib0048","first-page":"100049","article-title":"Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model","volume":"2","author":"Varela-Moreira","year":"2020","journal-title":"Int J Pharmac X"},{"key":"10.1016\/j.xphs.2023.08.026_bib0049","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.msec.2019.01.066","article-title":"Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer","volume":"98","author":"Kalyane","year":"2019","journal-title":"Mater Sci Eng C"},{"issue":"11","key":"10.1016\/j.xphs.2023.08.026_bib0050","doi-asserted-by":"crossref","first-page":"10505","DOI":"10.1021\/acsami.8b21609","article-title":"Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers","volume":"11","author":"Tahmasbi Rad","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"17","key":"10.1016\/j.xphs.2023.08.026_bib0051","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.xphs.2023.08.026_bib0052","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2018.02.008","article-title":"Colorectal cancer lung metastasis treatment with polymer\u2013drug nanoparticles","volume":"275","author":"Rychahou","year":"2018","journal-title":"J Controlled Release"},{"issue":"4","key":"10.1016\/j.xphs.2023.08.026_bib0053","first-page":"444","article-title":"Size, shape, charge and \u201cstealthy\u201d surface: Carrier properties affect the drug circulation time in vivo","volume":"16","author":"Di","year":"2021","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.08.026_bib0054","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2020.02.004","article-title":"Hyperthermia and smart drug delivery systems for solid tumor therapy","volume":"163","author":"Seynhaeve","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"10.1016\/j.xphs.2023.08.026_bib0055","doi-asserted-by":"crossref","first-page":"1906745","DOI":"10.1002\/adma.201906745","article-title":"A size-changeable collagenase-modified nanoscavenger for increasing penetration and retention of nanomedicine in deep tumor tissue","volume":"32","author":"Xu","year":"2020","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/j.xphs.2023.08.026_bib0056","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4172\/1948-5956.1000382","article-title":"Recent advances in targeting tumor energy metabolism with tumor acidosis as a biomarker of drug efficacy","volume":"8","author":"Akhenblit","year":"2016","journal-title":"J Cancer Sci Ther"},{"key":"10.1016\/j.xphs.2023.08.026_bib0057","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10555-019-09782-9","article-title":"Imaging tumor acidosis: a survey of the available techniques for mapping in vivo tumor pH","volume":"38","author":"Anemone","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.xphs.2023.08.026_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2008.03.011","article-title":"Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression","author":"Fang","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.xphs.2023.08.026_bib0059","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10555-019-09792-7","article-title":"Causes, consequences, and therapy of tumors acidosis","volume":"38","author":"Pillai","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.xphs.2023.08.026_bib0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10555-018-09777-y","article-title":"Tumor pH and metastasis: a malignant process beyond hypoxia","volume":"38","author":"Thews","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0061","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrc1713","article-title":"The role of disturbed pH dynamics and the Na+\/H+ exchanger in metastasis","volume":"5","author":"Cardone","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.xphs.2023.08.026_bib0062","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.addr.2009.04.016","article-title":"Intelligent polymeric micelles from functional poly (ethylene glycol)-poly (amino acid) block copolymers","volume":"61","author":"Bae","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2023.08.026_bib0063","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1007\/s11095-016-1981-6","article-title":"A computational\/experimental assessment of antitumor activity of polymer nanoassemblies for ph-controlled drug delivery to primary and metastatic tumors","volume":"33","author":"Curtis","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2023.08.026_bib0064","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s11095-014-1573-2","article-title":"Release, partitioning, and conjugation stability of doxorubicin in polymer micelles determined by mechanistic modeling","volume":"32","author":"Ponta","year":"2015","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.08.026_bib0065","first-page":"1","article-title":"H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.xphs.2023.08.026_bib0066","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.xphs.2023.08.026_bib0067","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.1009","article-title":"The ubiquitin-proteasome pathway and proteasome inhibitors","volume":"21","author":"Myung","year":"2001","journal-title":"Med Res Rev"},{"issue":"21","key":"10.1016\/j.xphs.2023.08.026_bib0068","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1200\/JCO.2005.05.081","article-title":"The ubiquitin-proteasome pathway and its role in cancer","volume":"23","author":"Mani","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923003611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923003611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:43:15Z","timestamp":1758361395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923003611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0022354923003611"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.08.026","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}